Article info
Commentary
General medicine
Edoxaban is non-inferior to low-molecular-weight heparin for treating cancer-associated venous thromboembolism
- Correspondence to Dr Lori-Ann Linkins MD, MSc and FRCPC, Hematology, McMaster University Department of Medicine, Hamilton, Ontario L8S 4K1, Canada; linkinla{at}mcmaster.ca
Citation
Edoxaban is non-inferior to low-molecular-weight heparin for treating cancer-associated venous thromboembolism
Publication history
- Received June 11, 2018
- First published June 29, 2018.
Online issue publication
November 21, 2018
Article Versions
- Previous version (29 June 2018).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2018. No commercial re-use. See rights and permissions. Published by BMJ.